Effects of Vitamin C, Vitamin D3, Coenzyme Q10 and antioxidant formula of different supplement forms on micronutrient, biomarker blood levels and quality of life

Phase 4

Recruiting

• Conditions: Different formula of supplement on micronutrient, blood biomarker and QoL; VitaminC; VitaminD3; CoenzymeQ10; Antioxidant; Quality of life

• Registration Number: TCTR20190205002
• Lead Sponsor: A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-02-05
• Study Completion: 2019-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1.Subjects aged ≥ 18 years who visit Vital-life wellness center for micronutrient level assessment and decide to receive either Vitamin C, Vitamin D3, CO-Q10 and antioxidant formula of HCK® or The original VTL supplement of Vitamin C, Vitamin D3, CO-Q10 and antioxidant or no supplement after discussion for possible treatment options with physician as usual practice
2.Subjects found to have low level of 25-(OH)D3/D2 (having 25-(OH)D3/D2 level 20-29 ng/ml) with the symptoms or feelings of low energy, lack of vitality or tiredness
3.Subjects who have not taken coenzyme Q10, vitamin C, vitamin D3, vitamin E, carotenoids, and flavonoids for at least 3 months and vitamin A for at least 6 months
4.Willing and able to comply with study procedure.

Exclusion Criteria

1.Subjects with poorly controlled underlying diseases such as poor control of Blood
Pressure (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg), poor control of blood sugar (HbA1c > 7%).
2.Subjects with eGFR < 30 ml/min/1.73 m2
3.Female subjects who are pregnant or lactating, or plan to have children (a negative
serum or urine pregnancy test is required on the screening day for women of child-bearing potential).
4. Subjects with diseases that may interfere with supplement absorption e.g., patients
with malabsorption and bowel surgery.
5. Subjects using medication that may interfere with micronutrient levels such as acid
suppressants, antacids, antiepileptic drugs (i.e., phenobarbital, valproic acid,
carbamazepine, phenytoin), and antipsychotic drugs (i.e., tricyclic antidepressants and
haloperidol). However, subjects who stop using these medications for at least 1 month
prior to the enrollment can be included into the study.
6. Subjects with vitamin D deficiency or having underlying diseases that require
treatment with vitamin D such as osteoporosis and primary hyperparathyroidism
7. Subjects who is currently smoking.
8. Subjects with history of allergy to vitamins and supplements

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Selected micronutrient levels month3 and month 6 STATA

Secondary Outcome Measures

Name	Time	Method
QoL month3 and month6 Chi square